BTAI Stock Forecast 2025-2026
Distance to BTAI Price Targets
BTAI Price Momentum
10 Quality Stocks Worth Considering Now
Researching Bioxcel (BTAI) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BTAI and similar high-potential opportunities.
Latest BTAI Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, BTAI has a neutral consensus with a median price target of $32.00 (ranging from $4.00 to $80.00). Currently trading at $2.13, the median forecast implies a 1,402.3% upside. This outlook is supported by 2 Buy, 1 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Colin Bristow at UBS, suggesting a 87.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BTAI Analyst Ratings
BTAI Price Target Range
Latest BTAI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BTAI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 30, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $3.00 |
| Jan 7, 2025 | B of A Securities | Geoff Meacham | Underperform | Downgrade | $0.25 |
| Jan 6, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $5.00 |
| Oct 21, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $5.00 |
| Sep 6, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Aug 30, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $7.00 |
| Aug 9, 2024 | UBS | Colin Bristow | Neutral | Maintains | $1.00 |
| Aug 8, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| Jun 27, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $7.00 |
| May 10, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Apr 23, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Mar 18, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $11.00 |
| Mar 14, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $7.00 |
| Mar 13, 2024 | B of A Securities | Geoff Meacham | Buy | Maintains | $7.00 |
| Feb 21, 2024 | UBS | Colin Bristow | Neutral | Downgrade | $4.00 |
| Nov 15, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $11.00 |
| Oct 31, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $11.00 |
| Oct 26, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $11.00 |
| Oct 5, 2023 | Truist Securities | Robyn Karnauskas | Hold | Downgrade | $0.00 |
| Sep 13, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $11.00 |
BioXcel Therapeutics Inc. (BTAI) Competitors
The following stocks are similar to Bioxcel based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BioXcel Therapeutics Inc. (BTAI) Financial Data
BioXcel Therapeutics Inc. has a market capitalization of $7.23M with a P/E ratio of -0.3x. The company generates $2.28M in trailing twelve-month revenue with a 8.7% profit margin.
Revenue growth is -37.2% quarter-over-quarter, while maintaining an operating margin of -6,420.6% and return on equity of +316.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
BioXcel Therapeutics Inc. (BTAI) Business Model
About BioXcel Therapeutics Inc.
Develops AI-driven treatments in biotechnology.
The company utilizes artificial intelligence and machine learning to analyze big data for identifying new treatment pathways, particularly in neurodegenerative and rare oncology conditions. By streamlining drug development processes, BioXcel Therapeutics generates revenue through innovative biopharmaceutical solutions that address unmet medical needs.
Headquartered in Connecticut, BioXcel Therapeutics is at the forefront of integrating technology with healthcare, contributing significantly to precision medicine and the advancement of transformative therapeutic candidates. The company plays a vital role in responding to the urgent demand for novel treatments in complex medical areas.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
74
CEO
Dr. Vimal D. Mehta Ph.D.
Country
United States
IPO Year
2018
Website
www.bioxceltherapeutics.comBioXcel Therapeutics Inc. (BTAI) Latest News & Analysis
Topline data for IGALMI® label expansion in home settings is expected in the second half of 2025, potentially supporting a supplemental New Drug Application (sNDA).
The timeline for topline data and potential label expansion of IGALMI® could impact market perceptions and valuations, influencing investment decisions based on growth prospects.
Data is being gathered to support a potential supplemental New Drug Application (sNDA) for expanding the label of IGALMI® for use in home settings.
The potential label expansion for IGALMI® may lead to increased sales and market share, positively impacting the company's revenue and stock performance.
BioXcel Therapeutics announced that the FDA has closed its inspection of a site in the TRANQUILITY II trial, supporting data reliability for BXCL501.
The FDA's closure of the inspection supports the reliability of BXCL501 trial data, potentially enhancing BioXcel's credibility and paving the way for regulatory approval, impacting stock performance.
BioXcel Therapeutics (Nasdaq: BTAI) has secured a $14 million registered direct offering, selling 4 million shares at $3.50 each, along with warrants for an additional 4 million shares.
BioXcel Therapeutics is raising $14 million through a direct stock offering, which signals potential growth opportunities but could dilute existing shares, impacting shareholder value.
BioXcel Therapeutics closed a direct offering of 4 million shares at $3.50 each, raising approximately $14 million. Accompanying warrants for 4 million shares at $4.20 are included.
BioXcel's $14 million capital raise through a direct offering indicates strong investor interest and funding for its AI-driven neuroscience projects, potentially impacting future growth and stock performance.
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
12 days agoBioXcel Therapeutics (BTAI) is not expected to meet earnings expectations in its upcoming report due to a lack of the necessary key ingredients for a positive outcome.
BioXcel Therapeutics may underperform in its upcoming earnings report due to missing key indicators, potentially leading to a negative market reaction and impacting stock performance.
Frequently Asked Questions About BTAI Stock
What is BioXcel Therapeutics Inc.'s (BTAI) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, BioXcel Therapeutics Inc. (BTAI) has a median price target of $32.00. The highest price target is $80.00 and the lowest is $4.00.
Is BTAI stock a good investment in 2025?
According to current analyst ratings, BTAI has 2 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $2.13. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BTAI stock?
Wall Street analysts predict BTAI stock could reach $32.00 in the next 12 months. This represents a 1,402.3% increase from the current price of $2.13. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is BioXcel Therapeutics Inc.'s business model?
The company utilizes artificial intelligence and machine learning to analyze big data for identifying new treatment pathways, particularly in neurodegenerative and rare oncology conditions. By streamlining drug development processes, BioXcel Therapeutics generates revenue through innovative biopharmaceutical solutions that address unmet medical needs.
What is the highest forecasted price for BTAI BioXcel Therapeutics Inc.?
The highest price target for BTAI is $80.00 from at , which represents a 3,655.9% increase from the current price of $2.13.
What is the lowest forecasted price for BTAI BioXcel Therapeutics Inc.?
The lowest price target for BTAI is $4.00 from Colin Bristow at UBS, which represents a 87.8% increase from the current price of $2.13.
What is the overall BTAI consensus from analysts for BioXcel Therapeutics Inc.?
The overall analyst consensus for BTAI is neutral. Out of 10 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $32.00.
How accurate are BTAI stock price projections?
Stock price projections, including those for BioXcel Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
